Redmile Group, LLC 的 Form 4 申報
ADC Therapeutics SAADCT,2026/4/2 申報
- 申報編號
- 0001104659-26-039359
- 申報時間
- 2026/4/2 21:00 ET
- 交易日
- 2026/3/31-4/2
- 申報延遲
- 2 天
- 10b5-1 計畫
- 沒有勾選
這份申報列了 6 筆非衍生性交易。公開市場賣出合計 $1,964 萬。交易後 2 天申報。
申報人
一份 Form 4 可以有好幾位申報人,例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Redmile Group, LLCCIK 0001425738 | 持股 10% 以上大股東 |
| Green JeremyCIK 0001650527 | 持股 10% 以上大股東 |
| RedCo II Master Fund, L.P.CIK 0001921783 | 持股 10% 以上大股東 |
非衍生性證券(表 I)
普通股等股票的取得與處分,每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/3/31 | Common Stock | S賣出處分 | −196,229 | $3.75F3 | −$736,251.21 | 15,470,502 | 間接 | |
| 2026/3/31 | Common Stock | S賣出處分 | −188,407 | $3.75F3 | −$706,903.06 | 12,957,305 | 直接 | |
| 2026/4/1 | Common Stock | S賣出處分 | −169,265 | $3.80F4 | −$643,037.74 | 15,301,237 | 間接 | |
| 2026/4/1 | Common Stock | S賣出處分 | −162,517 | $3.80F4 | −$617,402.08 | 12,794,788 | 直接 | |
| 2026/4/2 | Common Stock | S賣出處分 | −2,634,506 | $3.28F5 | −$8,638,545.17 | 12,666,731 | 間接 | |
| 2026/4/2 | Common Stock | S賣出處分 | −2,529,491 | $3.28F5 | −$8,294,200.99 | 10,265,297 | 直接 |
附註與備註
本站收錄交易價格引用的附註、修正申報(Form 4/A)的全部附註,以及申報的備註。其他附註,例如間接持有的方式、交易計畫的細節,請看 SEC EDGAR 上的原文。
- F3
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.63 to $3.81, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.
表 I 有 2 筆交易的價格引用這則附註。
- F4
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.70 to $3.83, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.
表 I 有 2 筆交易的價格引用這則附註。
- F5
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.25 to $3.77, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.
表 I 有 2 筆交易的價格引用這則附註。
備註
The sales reported herein were effected within a period of less than six months from the purchases of pre-funded warrants to purchase the Issuers' Common Stock reported in the Form 4 filed by the Reporting Persons on October 28, 2025. However, the sales reported herein were effected at a price lower than the previous purchases that were reported in the Form 4 filed on October 28, 2025, such that no profits have been earned by the Reporting Persons, and so the Reporting Persons have no additional liability under Section 16(b).